TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
基本信息
- 批准号:6241911
- 负责人:
- 金额:$ 16.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-08-01 至 1998-07-31
- 项目状态:已结题
- 来源:
- 关键词:age difference antileukocyte isoantibody artificial immunosuppression blood disorder chemotherapy bone marrow purging bone marrow transplantation busulfan clinical research combination chemotherapy cyclophosphamide dyserythropoietic anemia graft versus host disease histocompatibility typing homologous transplantation human subject human therapy evaluation myelofibrosis radiation immunosuppression relapse /recurrence tissue /cell culture transplant rejection
项目摘要
Allogeneic stem cell transplantation is the only known curative treatment
for myelodysplasia (MDS). The disease is heterogeneous and our previous
experience suggests that it is possible to adjust transplant approaches to
specific clinical situations. In patients with less advanced MDS (that is,
MDS without excess blasts) the risk of relapse after conventional
transplant preparative regimens of cyclophosphamide (CY) and total body
irradiation (TBI) or busulfan (BU) and CT is less than 5% and the major
cause of failure is treatment-related fatality. In such patients
undergoing human leukocyte antigen (HLA)-identical related donor
transplantation, a regimen of CY-TBI with liver and lung shielding will be
evaluated to estimate whether this approach can reduce treatment-related
fatality without an increase in relapse. In patients with less advanced
MDS undergoing unrelated donor transplantation, to retain sufficient
immunosuppression while reducing toxicity of the cytotoxic component, a
regimen of BU-CY with pharmacokinetic targeting of BU levels will be
evaluated. In patients with advanced MDS (that is, MDS with excess blasts
or chronic myelomonocytic leukemia) conventional preparative regimens
result in high relapse rates and intensified preparative regimens such as
BU-CY-TBI reduce relapse but increase toxicity. In such patients under age
56, we will test whether a regimen of BU-TBI retains the superior anti-
tumor effect of BU-CY-TBI, but reduces toxicity. In older patients with
advanced MDS, fatal toxicity of the transplant procedure is high and
therefor the regimen of BU-CY with pharmacokinetic targeting of BU levels
will be tested. Myelofibrosis is a related clonal myeloid disorder in
which progressive fibrosis results in life-threatening cytopenias and
organomegaly. Stem cell transplantation offers curative treatment to such
patients but has rarely been attempted. The feasibility of allogeneic
transplantation in patients with underlying myeloproliferative disorders
associated with marrow fibrosis will be tested.
同种异体干细胞移植是唯一已知的治疗方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FREDERICK APPLEBAUM其他文献
FREDERICK APPLEBAUM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FREDERICK APPLEBAUM', 18)}}的其他基金
TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
- 批准号:
6338859 - 财政年份:2000
- 资助金额:
$ 16.81万 - 项目类别:
TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
- 批准号:
6202257 - 财政年份:1999
- 资助金额:
$ 16.81万 - 项目类别:
TRANSPLANTATION FOR MYELODYSPLASIA AND MYELOFIBROSIS
骨髓增生异常和骨髓纤维化的移植
- 批准号:
6109817 - 财政年份:1998
- 资助金额:
$ 16.81万 - 项目类别:
AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE NONLYMPHOBLATIC LEUKEMI
急性非淋巴细胞白血病患者的自体骨髓移植
- 批准号:
3817222 - 财政年份:
- 资助金额:
$ 16.81万 - 项目类别:
AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH MALIGNANT LYMPHOMA
恶性淋巴瘤患者的自体骨髓移植
- 批准号:
3807909 - 财政年份:
- 资助金额:
$ 16.81万 - 项目类别:
AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH MALIGNANT LYMPHOMA
恶性淋巴瘤患者的自体骨髓移植
- 批准号:
3817223 - 财政年份:
- 资助金额:
$ 16.81万 - 项目类别: